Oral retinoids and plasma lipids

Dermatologic Therapy

Volumn 26, Issue 5, 2013, Pages 404-410

  Lilley, Jessica S ^a   Linton, Macrae F ^a   Fazio, Sergio ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

drug induced dyslipidemia; retinoid; rexinoid; secondary hypertriglyceridemia

Indexed keywords

ALITRETINOIN; ANDROGEN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BEXAROTENE; CYCLOSPORIN A; CYTOCHROME P450 3A4; DOCOSAHEXAENOIC ACID; ESTROGEN; FIBRIC ACID DERIVATIVE; FISH OIL; GEMFIBROZIL; GLUCOCORTICOID; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; ICOSAPENTAENOIC ACID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; OMEGA 3 ACID ETHYL ESTER; OMEGA 3 FATTY ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PHENOTHIAZINE DERIVATIVE; PROTEINASE INHIBITOR; RETINOIC ACID DERIVATIVE; RETINOID; THIAZIDE DIURETIC AGENT; THYROID HORMONE RECEPTOR; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN; VITAMIN D RECEPTOR;

AEROBIC EXERCISE; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL METABOLISM; CLINICAL PRACTICE; DISEASE SEVERITY; DYSLIPIDEMIA; FAMILIAL HYPERCHOLESTEROLEMIA; FAT INTAKE; FOLLOW UP; FREE THYROXINE INDEX; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; HYPOTHYROIDISM; INSULIN RESISTANCE; LIFESTYLE MODIFICATION; LIPID BLOOD LEVEL; LIPID METABOLISM; LONG TERM EXPOSURE; LYSOSOME STORAGE DISEASE; MONOTHERAPY; NEPHROTIC SYNDROME; OBESITY; PANCREATITIS; PHYSICAL ACTIVITY; PROTEIN EXPRESSION; WEIGHT REDUCTION;

DRUG-INDUCED DYSLIPIDEMIA; RETINOID; REXINOID; SECONDARY HYPERTRIGLYCERIDEMIA;

CARDIOVASCULAR DISEASES; DRUG MONITORING; DYSLIPIDEMIAS; HUMANS; LIPID METABOLISM; LIPIDS; RETINOIDS; RISK FACTORS; SKIN; SKIN DISEASES; TRIGLYCERIDES;

EID: 84885443299     PISSN: 13960296     EISSN: 15298019     Source Type: Journal    
DOI: 10.1111/dth.12085     Document Type: Article

References (42)

1. Feingold KR,. The outer frontier: the importance of lipid metabolism in the skin. J Lipid Res 2009: 50 (Suppl.): S417-S422.
2. Young SG, Davies BS, Fong LG, et al. GPIHBP1: an endothelial cell molecule important for the lipolytic processing of chylomicrons. Curr Opin Lipidol 2007: 18: 389-396.
3. Goldstein JL, Brown MS,. Progress in understanding the LDL receptor and HMG-CoA reductase, two membrane proteins that regulate the plasma cholesterol. J Lipid Res 1984: 25: 1450-1461.
4. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001: 285: 2486-2497.
5. Austin MA, Hokanson JE, Edwards KL,. Hypertriglyceridemia as a cardiovascular risk factor. Am J Cardiol 1998: 81: 7B-12B.
6. Yadav D, Pitchumoni CS,. Issues in hyperlipidemic pancreatitis. J Clin Gastroenterol 2003: 36: 54-62.
7. Gordon DJ, Probstfield JL, Garrison RJ, et al. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 1989: 79: 8-15.
8. Kontush A, Chapman MJ,. Functionally defective high-density lipoprotein: a new therapeutic target at the crossroads of dyslipidemia, inflammation, and atherosclerosis. Pharmacol Rev 2006: 58: 342-374.
9. Boden WE, Probstfield JL, Anderson T, et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 2011: 365: 2255-2267.
10. Barter PJ, Rye KA,. Cholesteryl ester transfer protein inhibition as a strategy to reduce cardiovascular risk. J Lipid Res 2012: 53: 1755-1766.
11. Feingold KR,. Thematic review series: skin lipids. The role of epidermal lipids in cutaneous permeability barrier homeostasis. J Lipid Res 2007: 48: 2531-2546.
12. Rodondi N, Darioli R, Ramelet AA, et al. High risk for hyperlipidemia and the metabolic syndrome after an episode of hypertriglyceridemia during 13-cis retinoic acid therapy for acne: a pharmacogenetic study. Ann Intern Med 2002: 136: 582-589.
13. Keller H, Dreyer C, Medin J, Mahfoudi A, Ozato K, Wahli W,. Fatty acids and retinoids control lipid metabolism through activation of peroxisome proliferator-activated receptor-retinoid X receptor heterodimers. Proc Natl Acad Sci U S A 1993: 90: 2160-2164.
14. Braissant O, Foufelle F, Scotto C, Dauca M, Wahli W,. Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat. Endocrinology 1996: 137: 354-366.
15. Staels B,. Regulation of lipid and lipoprotein metabolism by retinoids. J Am Acad Dermatol 2001: 45: S158-S167.
16. Klor HU, Weizel A, Augustin M, et al. The impact of oral vitamin A derivatives on lipid metabolism-what recommendations can be derived for dealing with this issue in the daily dermatological practice? J Dtsch Dermatol Ges 2011: 9: 600-606.
17. Jiang YJ, Lu B, Kim P, et al. PPAR and LXR activators regulate ABCA12 expression in human keratinocytes. J Invest Dermatol 2008: 128: 104-109.
18. Sparks JD, Dong HH,. FoxO1 and hepatic lipid metabolism. Curr Opin Lipidol 2009: 20: 217-226.
19. Zane LT, Leyden WA, Marqueling AL, Manos MM,. A population-based analysis of laboratory abnormalities during isotretinoin therapy for acne vulgaris. Arch Dermatol 2006: 142: 1016-1022.
20. Alcalay J, Landau M, Zucker A,. Analysis of laboratory data in acne patients treated with isotretinoin: is there really a need to perform routine laboratory tests? J Dermatolog Treat 2001: 12: 9-12.
21. Otley CC, Stasko T, Tope WD, Lebwohl M,. Chemoprevention of nonmelanoma skin cancer with systemic retinoids: practical dosing and management of adverse effects. Dermatol Surg 2006: 32: 562-568.
22. Barth JH, Macdonald-Hull SP, Mark J, Jones RG, Cunliffe WJ,. Isotretinoin therapy for acne vulgaris: a re-evaluation of the need for measurements of plasma lipids and liver function tests. Br J Dermatol 1993: 129: 704-707.
23. Targretin package insert. http://www.accessdata.fda.gov/drugsatfda-docs/ label/1999/21055lbl.pdf. Accessed September 10, 2013.
24. Scarisbrick JJ, Morris S, Azurdia R, et al. U.K. consensus statement on safe clinical prescribing of bexarotene for patients with cutaneous T-cell lymphoma. Br J Dermatol 2013: 168 (1): 192-200.
25. McCarter TL, Chen YK,. Marked hyperlipidemia and pancreatitis associated with isotretinoin therapy. Am J Gastroenterol 1992: 87: 1855-1858.
26. Toth PP, Potter D, Ming EE,. Prevalence of lipid abnormalities in the United States: the National Health and Nutrition Examination Survey 2003-2006. J Clin Lipidol 2012: 6: 325-330.
27. Dedoussis GV, Schmidt H, Genschel J,. LDL-receptor mutations in Europe. Hum Mutat 2004: 24: 443-459.
28. Gorkin JU, Watson K, Knopp RH,. Strategies for reducing cardiovascular risk in patients with hypertriglyceridemia. J Fam Pract 2007: 56: S1-S7, quiz S8.
29. Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009: 120: 1640-1645.
30. Hachem SB, Mooradian AD,. Familial dyslipidaemias: an overview of genetics, pathophysiology and management. Drugs 2006: 66: 1949-1969.
31. Eckel RH,. Lipoprotein lipase. A multifunctional enzyme relevant to common metabolic diseases. N Engl J Med 1989: 320: 1060-1068.
32. Crook D, Cust MP, Gangar KF, et al. Comparison of transdermal and oral estrogen-progestin replacement therapy: effects on serum lipids and lipoproteins. Am J Obstet Gynecol 1992: 166: 950-955.
33. Miller M, Stone NJ, Ballantyne C, et al. Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. Circulation 2011: 123: 2292-2333.
34. Qi K, Fan C, Jiang J, et al. Omega-3 fatty acid containing diets decrease plasma triglyceride concentrations in mice by reducing endogenous triglyceride synthesis and enhancing the blood clearance of triglyceride-rich particles. Clin Nutr 2008: 27: 424-430.
35. Harris WS,. n-3 fatty acids and serum lipoproteins: human studies. Am J Clin Nutr 1997: 65: 1645S-1654S.
36. GISSI-Prevenzione Investigators (Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico). Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico. Lancet 1999: 354: 447-455.
37. Yokoyama M, Origasa H, Matsuzaki M, et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet 2007: 369: 1090-1098.
38. Jacobson TA,. A new pure omega-3 eicosapentaenoic acid ethyl ester (AMR101) for the management of hypertriglyceridemia: the MARINE trial. Expert Rev Cardiovasc Ther 2012: 10: 687-695.
39. Ballantyne CM, Bays HE, Kastelein JJ, et al. Efficacy and safety of eicosapentaenoic acid ethyl ester (AMR101) therapy in statin-treated patients with persistent high triglycerides (from the ANCHOR study). Am J Cardiol 2012: 110: 984-992.
40. Berglund L, Brunzell JD, Goldberg AC, et al. Evaluation and treatment of hypertriglyceridemia: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2012: 97: 2969-2989.
41. Maki KC, Bays HE, Dicklin MR,. Treatment options for the management of hypertriglyceridemia: strategies based on the best-available evidence. J Clin Lipidol 2012: 6: 413-426.
42. Beach RA, McQueen M, Wismer J,. Novel management of isotretinoin-induced hypertriglyceridemia in an adolescent with severe acne. Clin Pediatr (Phila) 2009: 48: 551-554.